101 related articles for article (PubMed ID: 10718144)
41. 3D calculation of absorbed dose for 131I-targeted radiotherapy: a Monte Carlo study.
Saeedzadeh E; Sarkar S; Abbaspour Tehrani-Fard A; Ay MR; Khosravi HR; Loudos G
Radiat Prot Dosimetry; 2012 Jul; 150(3):298-305. PubMed ID: 22069233
[TBL] [Abstract][Full Text] [Related]
42. Ideal dose level in treatment planning optimization.
Begnozzi L; Malaspina F; Gentile FP; Chiatti L; Carpino S; Fragomeni R; Benassi M
Strahlenther Onkol; 1992 Oct; 168(10):588-92. PubMed ID: 1440230
[TBL] [Abstract][Full Text] [Related]
43. Confidence intervals in dose volume histogram computation.
Cutanda Henríquez F; Vargas Castrillón S
Med Phys; 2010 Apr; 37(4):1545-53. PubMed ID: 20443475
[TBL] [Abstract][Full Text] [Related]
44. The influence of repopulation kinetics on isoeffect doses for permanent implants.
Kneschaurek P
Strahlenther Onkol; 1994 Oct; 170(10):602-7. PubMed ID: 7974172
[TBL] [Abstract][Full Text] [Related]
45. Impact of dose and sensitivity heterogeneity on TCP.
Wiklund K; Toma-Dasu I; Lind BK
Comput Math Methods Med; 2014; 2014():182935. PubMed ID: 24899915
[TBL] [Abstract][Full Text] [Related]
46. Microdosimetry and radiocurability: modelling targeted therapy with beta-emitters.
Nahum AE
Phys Med Biol; 1996 Oct; 41(10):1957-72. PubMed ID: 8912374
[TBL] [Abstract][Full Text] [Related]
47. Some characteristics of tumour control probability for heterogeneous tumours.
Ebert MA; Hoban PW
Phys Med Biol; 1996 Oct; 41(10):2125-33. PubMed ID: 8912385
[TBL] [Abstract][Full Text] [Related]
48. Comparison of DVH data from multiple radiotherapy treatment planning systems.
Ebert MA; Haworth A; Kearvell R; Hooton B; Hug B; Spry NA; Bydder SA; Joseph DJ
Phys Med Biol; 2010 Jun; 55(11):N337-46. PubMed ID: 20463378
[TBL] [Abstract][Full Text] [Related]
49. Implications of nonuniform tumor doses for radioimmunotherapy.
O'Donoghue JA
J Nucl Med; 1999 Aug; 40(8):1337-41. PubMed ID: 10450686
[TBL] [Abstract][Full Text] [Related]
50. Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry.
Prideaux AR; Song H; Hobbs RF; He B; Frey EC; Ladenson PW; Wahl RL; Sgouros G
J Nucl Med; 2007 Jun; 48(6):1008-16. PubMed ID: 17504874
[TBL] [Abstract][Full Text] [Related]
51. Investigation of four-dimensional (4D) Monte Carlo dose calculation in real-time tumor tracking stereotatic body radiotherapy for lung cancers.
Chan MK; Kwong DL; Ng SC; Tam EK; Tong AS
Med Phys; 2012 Sep; 39(9):5479-87. PubMed ID: 22957615
[TBL] [Abstract][Full Text] [Related]
52. A new method for optimum dose distribution determination taking tumour mobility into account.
Stavrev PV; Stavreva NA; Round WH
Phys Med Biol; 1996 Sep; 41(9):1679-89. PubMed ID: 8884905
[TBL] [Abstract][Full Text] [Related]
53. Optimization of equivalent uniform dose using the L-curve criterion.
Chvetsov AV; Dempsey JF; Palta JR
Phys Med Biol; 2007 Oct; 52(19):5973-84. PubMed ID: 17881813
[TBL] [Abstract][Full Text] [Related]
54. The value of nonuniform margins for six-field conformal irradiation of localized prostate cancer.
Pickett B; Roach M; Verhey L; Horine P; Malfatti C; Akazawa C; Dea D; Varad B; Rathbun C; Phillips TL
Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):211-8. PubMed ID: 7721618
[TBL] [Abstract][Full Text] [Related]
55. Choline PET based dose-painting in prostate cancer--modelling of dose effects.
Niyazi M; Bartenstein P; Belka C; Ganswindt U
Radiat Oncol; 2010 Mar; 5():23. PubMed ID: 20298546
[TBL] [Abstract][Full Text] [Related]
56. Radiobiological impact of reduced margins and treatment technique for prostate cancer in terms of tumor control probability (TCP) and normal tissue complication probability (NTCP).
Jensen I; Carl J; Lund B; Larsen EH; Nielsen J
Med Dosim; 2011; 36(2):130-7. PubMed ID: 20488692
[TBL] [Abstract][Full Text] [Related]
57. Implementation of a model for estimating tumor control probability for an inhomogeneously irradiated tumor.
Niemierko A; Goitein M
Radiother Oncol; 1993 Nov; 29(2):140-7. PubMed ID: 8310139
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of external beam radiotherapy and brachytherapy for localized prostate cancer using equivalent uniform dose.
Wang JZ; Li XA
Med Phys; 2003 Jan; 30(1):34-40. PubMed ID: 12557976
[TBL] [Abstract][Full Text] [Related]
59. Assessment and quantification of patient set-up errors in nasopharyngeal cancer patients and their biological and dosimetric impact in terms of generalized equivalent uniform dose (gEUD), tumour control probability (TCP) and normal tissue complication probability (NTCP).
Boughalia A; Marcie S; Fellah M; Chami S; Mekki F
Br J Radiol; 2015 Jun; 88(1050):20140839. PubMed ID: 25882689
[TBL] [Abstract][Full Text] [Related]
60. Potential benefits of dosimetric VMAT tracking verified with 3D film measurements.
Crijns W; Defraene G; Van Herck H; Depuydt T; Haustermans K; Maes F; Van den Heuvel F
Med Phys; 2016 May; 43(5):2162. PubMed ID: 27147328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
